Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Tension between practitioners who believe autologous stem cells should be considered a service and the FDA, which considers some of them biologics, has come to a head in recent months. Laura DeFrancesco investigates.
Coinciding with last month's annual meeting of the American Society of Clinical Oncology, at least one business launched with a plan to use genetic information from patient tumors to help guide treatment. Michael Eisenstein investigates.
Since the discovery of circulating tumor cells in 1869, researchers have been able to do little else beyond count them. This is about to change, as advanced technologies for harvesting and analyzing rare cells from blood are opening the window for characterization. Jim Kling reports.
Comparative effectiveness, especially in its new guise of patient-centered outcomes research, is all the rage in US policy circles. Will it really make a difference to healthcare? Mark Ratner reports.
Encouraging more broad and inclusive data sharing in today's world will involve concerted community efforts to overcome technical barriers and human foibles. Vivien Marx investigates.
A new statistical method called MIC can find diverse types of correlations in large data sets. Nature Biotechnology asked eight experts to weigh in on its utility.
US biotech seems reenergized, but unsettled policy questions take a back seat to pending national elections, particularly with the presidency at stake. Jeffrey L Fox reports.
As parts of the developing world embrace biotech, the focus is shifting from food production to fuels, industrial chemicals and even drugs. Daniel Grushkin investigates.
New techniques for manipulating plant genomes are yielding plants touted as nontransgenic. Will that relieve regulatory burden? Emily Waltz investigates.
In spite of its modest performance in clinical trials, Benlysta may offer effective relief against lupus. But physicians are still working to identify the right patients. Michael Eisenstein reports.
